1. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat. Med. 1995; 1: 658-660. doi: 10.1038/nm0795-658
2. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011; 12: 570-584. doi: 10.1038/nrn3057
3. Cohen AS, Goadsby PJ. Functional neuroimaging of primary headache disorders. Expert Rev. Neurother. 2006; 6: 1159-1171. doi: 10.1586/14737175.6.8.1159
4. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol. Med. 2007; 13: 39-44. doi: 10.1016/j.molmed.2006.11.005
5. Samsam M. Central nervous system acting drugs in treatment of migraine headache. Cent Nerv Syst Agents Med Chem. 2012; 12(3): 158-172. doi: 10.2174/187152412802430147
6. Lazarov NE. Comparative analysis of the chemical neuroanatomy of the mammalian trigeminal ganglion and mesencephalic trigeminal nucleus. Prog Neurobiol. 2002; 66(1): 19-59. doi: 10.1016/S0301-0082(01)00021-1
7. Samsam M, Coveñas R, Ahangari R, Yajeya J. Major neuroanatomical and neurochemical substrates involved in primary headaches. Chapter 1. Neuroanatomy Research Advances; In: Flynn CE, Callaghan BR, eds. Nova Science Publishers; New York; 2009: 1- 58.
8. Samsam M, Coveñas R, Ahangari R, Yajeya J, Narváez JA, Tramu G. Simultaneous depletion of neurokinin A, substance P and calcitonin gene related peptide immunoreactivities in the caudal trigeminal nucleus of the rat following electrical stimulation of the Gasserian ganglion: a possible co-release of neuropeptides. PAIN. 2000; 84: 389-395. doi: 10.1016/s0304-3959(99)00240-7
9. Friberg L, Olesen J, Olsen TS, Karle A, Ekman R, Fahrenkrug J. Absence of vasoactive peptide release from brain to cerebral circulation during onset of migraine with aura. Cephalalgia. 1994; 14(1): 47-54. doi: 10.1046/j.1468-2982.1994.1401047.x
10. Gallai V, Sarchielli P, Floridi A. et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995; 15(5): 384-390. doi: 10.1046/j.1468-2982.1995.1505384.x
11. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002; 22(1): 54-61. doi: 10.1046/j.1468-2982.2002.00310.x
12. Olesen J, Diener HC, Husstedt IW, et al. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350(11): 1104-1110. doi: 10.1056/nejmoa030505
13. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-revised report of an EFNS task force. Eur. J. Neurol. 2009; 16: 968-981. doi: 10.1111/j.1468-1331.2009.02748.x
14. Humphrey PP. The discovery and development of the triptans, a major therapeutic breakthrough. Headache. 2008; 48: 685-687. doi: 10.1111/j.1526-4610.2008.01097.x
15. Bigal ME, Krymchantowski AV, Ho T. Migraine in the triptan era: progresses achieved, lessons learned and future developments. Arq. Neuropsiquiatr. 2009; 67: 559-569. doi: 10.1590/S0004-282X2009000300040
16. Ferrari MD, Färkkilä M, Reuter U, European COL-144 Investigators. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan-a randomised proof-of-concept trial. Cephalalgia. 2010; 30: 1170-1178. doi: 10.1177/0333102410375512
17. Samsam M, Coveñas R, Ahangari R, Yajeya J. Neuropeptides and other chemical mediators, and the role of anti-inflammatory drugs in primary headaches. AIAA-MC. 2010; 3: 170-188. doi: 10.2174/1871523011009030170
18. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982; 298: 240-244. doi: 10.1038/298240a0
19. Brain SD, MacIntyre I, Williams TJ. A second form of human calcitonin gene-related peptide which is a potent vasodilator. Eur J Pharmacol. 1986; 124(3): 349-352. doi: 10.1016/0014-2999(86)90238-4
20. Sternini C, Anderson K. Calcitonin gene-related peptide-containing neurons supplying the rat digestive system: differential distribution and expression pattern. Somatosens Mot Res. 1992; 9(1): 45-59. doi: 10.3109/08990229209144762
21. Ohno T, Hattori Y, Komine R, et al. Roles of calcitonin gene-related peptide in maintenance of gastric mucosal integrity and in enhancement of ulcer healing and angiogenesis. Gastroenterology. 2008; 134(1): 215-225. doi: 10.1053/j.gastro.2007.10.001
22. Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs. 2010; 24(7): 539-548. doi: 10.2165/11534920-000000000-00000
23. van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997; 21(5): 649-678. doi: 10.1016/s0149-7634(96)00023-1
24. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985; 313: 54-56. doi: 10.1038/313054a0
25. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann. Neurol. 2000; 47: 614-624.
26. Villalón CM, Centurión D, Valdivia LF, De Vries P, Saxena PR. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc. West Pharmacol. Soc. 2002; 45: 199-210.
27. Spierings ELH. Pathogenesis of the migraine attack. Clin. J. Pain. 2003; 19: 255-262.
28. Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia. 2004: 2: 2-7.
29. Kruuse C, Thomsen L, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain, 2003; 126: 241-247. doi: 10.1093/brain/awg009
30. Nichols FT 3rd, Mawad M, Mohr JP, Stein B, Hilal S, Michelsen WJ. Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke. 1990; 21(4): 555-559. doi: 10.1161/01.STR.21.4.555
31. Olesen J, Friberg L, Olsen TS, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol. 1990; 28(6): 791-798. doi: 10.1002/ana.410280610
32. May A, Büchel C, Turner R, Goadsby PJ. Magnetic resonance angiography in facial and other pain: neurovascular mechanisms of trigeminal sensation. J Cereb Blood Flow Metab. 2001; 21(10): 1171-1176. doi: 10.1097/00004647-200110000-00005
33. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998; 393: 333-339. doi: 10.1038/30666
34. Choksi T, Hay DL, Legon S, et al. Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines. Br J Pharmacol. 2002; 136(5): 784-792. doi: 10.1038/sj.bjp.0704761
35. Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002; 54(2): 233-246. doi: 10.1124/pr.54.2.233
36. Miller PS, Barwell J, Poyner DR, Wigglesworth MJ, Garland SL, Donnelly D. Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. Biochem. Biophys. Res. Commun. 2010; 391: 437-442. doi: 10.1016/j.bbrc.2009.11.076
37. Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem. 2002; 277(16): 14294-14298. doi: 10.1074/jbc.M109661200
38. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J. Neurosci., 2007; 27: 2693-2703. doi: 10.1523/jneurosci.4542-06.2007
39. Hay DL, Howitt SG, Conner AC, Doods H, Schindler M, Poyner DR. A comparison of the actions of BIBN4096BS and CGRP(8-37) on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells. Br J Pharmacol. 2002; 137(1): 80-86. doi: 10.1038/sj.bjp.0704844
40. Dennis T, Fournier A, Cadieux A, et al. hCGRP8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery. J. Pharmacol. Exp. Ther. 1990; 254: 123-128.
41. Hay DL, Poyner DR, Quirion R, et al. International Union of Pharmacology. International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor. Pharmacol. Rev. 2008; 60: 143-145. doi: 10.1124/pr.108.00372
42. Kitazono T, Heistad DD, Faraci FM. Role of ATP-sensitive K+ channels in CGRP-induced dilatation of basilar artery in vivo. Am J Physiol. 1993; 265(2 Pt 2): H581-H585.
43. Hong KW, Yoo SE, Yu SS, Lee JY, Rhim BY. Pharmacological coupling and functional role for CGRP receptors in the vasodilation of rat pial arterioles. Am J Physiol. 1996; 270(1 Pt 2): H317-H323.
44. Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia. 2006; 26(11): 1304-1309. doi: 10.1111/j.1468-2982.2006.01218.x
45. Bellamy J, Bowen EJ, Russo AF, Durham PL. Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur J Neurosci.2006; 23(8): 2057-2066. doi: 10.1111/j.1460-9568.2006.04742.x
46. Eftekhari S, Gaspar RC, Roberts R, et al. Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: a detailed study using in situ hybridization, immunofluorescence and autoradiography. J Comp Neurol. 2015. doi: 10.1002/cne.23828
47. Edvinsson L, Eftekhari S, Salvatore CA, Warfvinge K. Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. Mol Cell Neurosci. 2011; 46(1): 333-339. doi: 10.1016/j.mcn.2010.10.005
48. Ottosson A, Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia. 1997; 17(3): 166-174. doi: 10.1046/j.1468-2982.1997.1703166.x
49. Lennerz JK, Rühle V, Ceppa EP, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008; 507(3): 1277-1299. doi: 10.1002/cne.21607
50. Yu LC, Zheng EM, Lundeberg T. Calcitonin gene-related peptide 8-37 inhibits the evoked discharge frequency of wide dynamic range neurons in dorsal horn of the spinal cord in rats. Regul Pept. 1999; 83(1): 21-24. doi: 10.1016/S0167-0115(99)00046-4
51. Benemei S, De Cesaris F, Fusi C, Rossi E, Lupi C, Geppetti P. TRPA1 and other TRP channels in migraine. J Headache Pain. 2013; 14: 71.
52. Reddington M, Priller J, Treichel J, Haas C, Kreutzberg GW. Astrocytes and microglia as potential targets for calcitonin gene related peptide in the central nervous system. Can J Physiol Pharmacol. 1995; 73(7): 1047-1049.
53. Arulmani U, Gupta S, Massen Van Den Brink AM, Centurión D, Villalón CM, Saxena PR. Experimental migraine models and their relevance in migraine therapy. Cephalalgia, 2006; 26: 642-659. doi: 10.1111/j.1468-2982.2005.01082.x
54. Linde M. Migraine: a review and future directions for treatment. Acta Neurol. Scand., 2006; 114: 71-83. doi: 10.1111/j.1600-0404.2006.00670.x
55. Edvinsson L, Alm R, Shaw D, et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol. 2002; 434: 49-53. doi: 10.1016/S0014-2999(01)01532-1
56. Jansen-Olesen I, Jorgensen L, Engel U, Edvinsson L. In-depth characterization of CGRP receptors in human intracranial arteries. Eur. J. Pharmacol., 2003; 481: 207-216. doi: 10.1016/j.ejphar.2003.09.021
57. Wu D, Eberlein W, Rudolf K, Engel W, Hallermayer G, Doods H. Characterisation of calcitonin gene-related peptide receptors in rat atrium and vas deferens: evidence for a [Cys(Et)(2, 7)]hCGRP-preferring receptor. Eur. J. Pharmacol. 2000; 400: 313-319. doi: 10.1016/S0014-2999(00)00407-6
58. Jansen-Olesen I, Kaarill L, Edvinsson L. Characterization of CGRP(1) receptors in the guinea pig basilar artery. Eur. J. Pharmacol. 2001; 414: 249-258. doi: 10.1016/S0014-2999(01)00760-9
59. Wu D, Doods H, Arndt K, Schindler M. Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor heterogeneity. Biochem Soc Trans. 2002; 30: 468-473. doi: 10.1042/bst0300468
60. Gupta S, Akerman S, van den Maagdenberg AM, Saxena PR, Goadsby PJ, van den Brink AM. Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine. Cephalalgia. 2006, 26, 1294-303.
61. Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005; 25: 139-147. doi: 10.1111/j.1468-2982.2004.00830.x
62. Tröltzsch M, Denekas T, Messlinger K. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur J Pharmacol. 2007; 562: 103-110. doi: 10.1016/j.ejphar.2007.01.058
63. Gupta S, Mehrotra S, Villalon CM, et al. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur J Pharmacol. 2006; 530: 107-116. doi: 10.1016/j.ejphar.2005.11.020
64. Hasbak P, Saetrum Opgaard O, Eskesen K, et al. Investigation of CGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist. J. Pharmacol. Exp. Ther. 2003; 304: 326-333. doi: 10.1124/jpet.102.037754
65. Sixt ML, Messlinger K, Fischer MJ. Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain. 2009; 132: 3134-3141. doi: 10.1093/brain/awp168
66. Ho TW, Mannix LK, Fan X, et al. MK-0974 Protocol 004 study group. Collaborators (20), Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312.
67. Connor K.M, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977. doi: 10.1212/WNL.0b013e3181b87942
68. Iovino M, Feifel U, Yong CL, Wolters JM, Wallenstein G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia. 2004; 24: 645-656. doi: 10.1111/j.1468-2982.2004.00726.x
69. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008, 372: 2115-2123. doi: 10.1016/S0140-6736(08)61626-8
70. Summ O, Charbit AR, Andreou AP, Goadsby PJ. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain. 2010; 133(9): 2540-2548. doi: 10.1093/brain/awq224
71. Tepper SJ, Cleves C. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Curr. Opin. Investig. Drugs. 2009; 10: 711-720.
72. Tfelt-Hansen P, Olesen J. Possible site of action of CGRP antagonists in migraine. Cephalalgia. 2011; 31: 748-750. doi: 10.1177/0333102411398403
73. Diener HC, Barbanti P, Dahlöf C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011; 31(5): 573-584. doi: 10.1177/0333102410388435
74. Benemei S, Nicoletti P, Capone JA, Geppetti P. Pain pharmacology in migraine: focus on CGRP and CGRP receptors. Neurol. Sci., 2007, 28(Suppl 2): S89-S93. doi: 10.1007/s10072-007-0757-5
75. Villalón CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol. Ther., 2009; 124: 309-323. doi: 10.1016/j.pharmthera.2009.09.003
76. Karsan N, Goadsby PJ. Calcitonin gene-related peptide and migraine. Curr Opin Neurol. 2015; 28(3): 250-254.
77. Karsan N, Goadsby PJ. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep. 2015; 15(5): 25.
78. Hougaard A, Tfelt-Hansen P. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists. Expert Opin Drug Metab Toxicol. 2015; 22: 1-10.
79. Hoffmann J, Goadsby PJ. New agents for acute treatment of migraine: CGRP receptor antagonists, iNOS Inhibitors. Curr Treat Options Neurol. 2012; 14(1): 50-59. doi: 10.1007/s11940-011-0155-4
80. Tajti J, Csáti A, Vécsei L. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors. Expert Opin Drug Metab Toxicol. 2014; 10(11): 1509-1520.
81. Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015; 80(2): 193-199. doi: 10.1111/bcp.12618
82. Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015; 79(6): 886-895. doi: 10.1111/bcp.12591
83. Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014; 28(5): 389-399. doi: 10.1007/s40263-014-0156-4
84. Reuter U. Anti-CGRP antibodies: a new approach to migraine prevention. Lancet Neurol. 2014; 13(9): 857-859. doi: 10.1016/S1474-4422(14)70126-7
85. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol. 2002; 2(9): 706-713. doi: 10.1038/nri891
86. Nimmerjahn F, Gordan S, Lux A. FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol. 2015; 36(6): 325-336.
87. Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013; 53(8): 1230-1244. doi: 10.1111/head.12179
88. Alder Biopharmaceuticals, Inc. A parallel group, double-blind, randomized, placebo controlled dose-ranging phase 2 trial to evaluate the efficacy, safety, and pharmacokinetics of ALD403 administered intravenously in patients with chronic migraine. http://www.alderbio.com/clinical-trials/ 2013; Accessed August, 2015.
89. Alder Biopharmaceuticals, Inc. Safety tolerability and pharmacokinetics of ALD403. Available at: https://clinicaltrials.gov/ct2/show/NCT01579383?term=
ALD403&rank=1 2013; Accessed August, 2015.
90. Alder Biopharmaceuticals, Inc. Safety, efficacy and pharmacokinetics of ALD403. Available at: https://clinicaltrials.gov/ct2/show/NCT01772524?term
=ALD403&rank=3 2014; Accessed August, 2015.
91. Alder Biopharmaceuticals, Inc. A multicenter assessment of ALD403 in chronic migraine. https://clinicaltrials.gov/ct2/show/NCT02275117?term=ALD
403&rank=2 2015; Accessed August, 2015.
92. Dodick DW, Goadsby PJ, Silberstein SD, et al. ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014; 13(11): 1100-1107. doi: 10.1016/S1474-4422(14)70209-1
93. Eli Lilly and Company. CGRP mAb migraine prevention. Available at: http://www.lilly.com/SiteCollectionDocuments/Pipeline/Clinical%20Development%20Pipeline/10.html. Accessed in Aug 2015.
94. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014; 13(9): 885-892. doi: 10.1016/S1474-4422(14)70128-0
95. Eli Lilly and Company. A study of LY2951742 in healthy Japanese and Caucasian participants. Available at: https://clinicaltrials.gov/ct2/show/NCT02104765?term=LY2951742&rank=2 2015; Accessed August, 2015.
96. Eli Lilly and Compan. A study of LY2951742 in healthy volunteers. Available at: https://clinicaltrials.gov/ct2/show/NCT01337596?term=LY2951742&rank=5 2015; Accessed August, 2015.
97. Eli Lilly and Company. A study of LY2951742 in participants with migraine. Available at: https://clinicaltrials.gov/ct2/show/NCT01625988?term=LY2951742&rank=7 2015; Accessed August, 2015.
98. Vermeersch S, Benschop RJ, Van Hecken A, et al. Translational pharmacodynamics of CGRP monoclonal antibody LY2951742 in a capsaicin-induced dermal blood flow model. J Pharmacol Exp Ther. 2015; 354(3): 350-357.
99. Eli Lilly and Company. A Study of LY2951742 in Participants With Chronic Cluster Headache. Available at: https://clinicaltrials.gov/ct2/show/NCT02438826?term=LY2951742&rank=3 2015; Accessed August, 2015.
100. Teva to Present New Findings at the American Headache Society (AHS) Meeting – Analysis of Migraine Phase IIb Studies Provides Novel Insights into TEV-48125 Efficacy and Safety in Both Episodic & Chronic Migraine. Available at: http://news.tevausa.com/mobile.view?c=251945&v=203&d=1&id=2060482, 2015.
101. Schuster NM, Vollbracht S, Rapoport AM. Emerging treatments for the primary headache disorders. Neurol Sci. 2015; 36(Suppl 1): 109-113.
102. Walter S, Bigal ME. TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine. Curr Pain Headache Rep. 2015; 19(3): 6.
103. Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs. 2014; 6(4): 871-878.
104. Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013; 34(7): 483-492.
105. TEVA latest news. Available at: http://www.tevapharm.com/news/?itemid=%7B007EDCEC-98E8-41EA-8775-2F4E78BB12E6%7D 2015; Accessed 2015.
106. Amgen. Amgen To Present AMG 334 Data At 17th Congress of the International Headache Society: Data Evaluating Safety and Efficacy of AMG 334 Provides New Insights Into Preventive Treatment of Migraine. Available at: http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2015&releaseID=2046668. Accessed August, 2015.
107. Amgen. Ascending single doses of AMG 334 in healthy subjects and migraine patients. Available at: https://clinicaltrials.gov/ct2/show/NCT01688739?term=AMG+334&rank=1 2014; Accessed August, 2015.
108. Amgen. Ascending multiple-doses of AMG 334 in healthy subjects and in Migraine Patients. Available at: https://clinicaltrials.gov/ct2/show/NCT01723514?term=AMG+334&rank=3 2013; Accessed August, 2015.
109. Amgen. Ascending multiple-doses of AMG 334 in healthy subjects and in migraine patients. Available at: http://www.amgentrials.com/amgen/trialsummary.aspx?studyid=20101268. Accessed August, 2015.
110. Amgen. A phase 2 study to evaluate the efficacy and safety of AMG 334 in migraine prevention. Available at: https://clinicaltrials.gov/ct2/show/NCT01952574?term=AMG+334&rank=2 2015; Accessed August, 2015.
111. Amgen. A sudy to evaluate the efficacy and safety of AMG 334 in chronic migraine prevention. Available at: http://www.amgentrials.com/amgen/trialsummary.aspx?studyid=20120295 2015; Accessed August, 2015.
112. Amgen. A study to assess the long-term safety and efficacy of AMG 334 in chronic migraine prevention. Available at: http://www.amgentrials.com/amgen/trialsummary.aspx?studyid=20130255 2015; Accessed August, 2015.
113. Amgen. Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine. Available at: http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2015&releaseID=2061044 2015; Accessed September, 2015.
114. PRNewswire/THOUSAND OAKS, Calif. Amgen presents first phase 2 data for AMG 334 in the Prevention of Episodic Migraine. Available at: http://www.prnewswire.com/news-releases/amgen-presents-first-phase-2-data-for-amg-334-in-the-prevention-of-episodic-migraine-300084005.html 2015; Accessed May 15, 2015.
115. PRNewswire/ THOUSAND OAKS, Calif. Amgen Presents open-label extension data from ongoing phase 2 study of amg 334 in the prevention of episodic migraine: Available at: http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2015&releaseID=2061044 2015; Accessed June 19, 2015.
116. Nohr D, Weihe E. The neuroimmune link in the bronchus-associated lymphoid tissue (BALT) of cat and rat: peptides and neural markers. Brain Behav Immun. 1991; 5(1): 84-101.
117. Keith IM. The role of endogenous lung neuropeptides in regulation of the pulmonary circulation. Physiol Res. 2000; 49(5): 519-537.
118. Dakhama A, Larsen GL, Gelfand EW. Calcitonin gene-related peptide: role in airway homeostasis. Curr Opin Pharmacol. 2004; 4(3): 215-220.
119. Okajima K, Harada N. Regulation of inflammatory responses by sensory neurons: molecular mechanism(s) and possible therapeutic applications. Curr Med Chem. 2006; 13(19): 2241-2251.
120. Springer J, Geppetti P, Fischer A, Groneberg DA. Calcitonin gene-related peptide as inflammatory mediator. Pulm Pharmacol Ther. 2003; 16(3): 121-130.
121. Holzmann B. Antiinflammatory activities of CGRP modulating innate immune responses in health and disease. Curr Protein Pept Sci. 2013; 14(4): 268-274.
122. Alpaerts K, Buckinx R, Adriaensen D, Van Nassauw L, Timmermans JP. Identification and putative roles of distinct subtypes of intestinal dendritic cells in neuroimmune communication: what can be learned from other organ systems? Anat Rec (Hoboken). 2015; 298(5): 903-916. doi: 10.1002/ar.23106
123. Assas BM, Miyan JA, Pennock JL. Cross-talk between neural and immune receptors provides a potential mechanism of homeostatic regulation in the gut mucosa. Mucosal Immunol. 2014; 7(6): 1283-1289. doi: 10.1038/mi.2014.80
124. Evangelista S. Capsaicin receptor as target of calcitonin gene-related peptide in the gut. Prog Drug Res. 2014; 68: 259-276. doi: 10.1007/978-3-0348-0828-6_10
125. Taché Y, Garrick T, Raybould H. Central nervous system action of peptides to influence gastrointestinal motor function. Gastroenterology. 1990; 98(2): 517-528.
126. Demir IE, Schäfer KH, Tieftrunk E, Friess H, Ceyhan GO. Neural plasticity in the gastrointestinal tract: chronic inflammation, neurotrophic signals, and hypersensitivity. Acta Neuropathol. 2013; 125(4): 491-509. doi: 10.1007/s00401-013-1099-4
127. Gaete PS, Lillo MA, Figueroa XF. Functional role of connexins and pannexins in the interaction between vascular and nervous system. J Cell Physiol. 2014; 229(10): 1336-1345. doi: 10.1002/jcp.24563
128. Reuss S. Trigeminal innervation of the mammalian pineal gland. Microsc Res Tech. 1999; 46(4-5): 305-309. doi: 10.1002/(SICI)1097-0029(19990815/01)46:4/5<305::AID-JEMT7>3.0.CO;2-#
129. Vega AV, Avila G. CGRP, a vasodilator neuropeptide that stimulates neuromuscular transmission and EC coupling. Curr Vasc Pharmacol. 2010; 8(3): 394-403. doi: 10.2174/157016110791112287
130. Ishida K, Kawamata T, Tanaka S, Shindo T, Kawamata M. Calcitonin gene-related peptide is involved in inflammatory pain but not in postoperative pain. Anesthesiology. 2014; 121(5): 1068-1079. doi: 10.1097/ALN.0000000000000364
131. Nelson KB, Grether JK, Croen LA, et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol. 2001; 49: 597-606.
132. McNamara IM, Borella AW, Bialowas LA, Whitaker-Azmitia PM. Further studies in the developmental hyperserotonemia model (DHS) of autism: social, behavioral and peptide changes. Brain Res. 2008; 1189: 203-214.
133. Gabriele S, Sacco R, Persico AM. Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2014; 24(6): 919-929. doi: 10.1016/j.euroneuro.2014.02.004
134. Yang CJ, Tan HP, Du YJ. The developmental disruptions of serotonin signaling may involved in autism during early brain development. Neuroscience. 2014; 267: 1-10. doi: 10.1016/j.neuroscience.2014.02.021
135. Miles JH. Autism spectrum disorders–a genetics review. Genet Med. 2011; 13(4): 278-294. doi: 10.1097/GIM.0b013e3181ff67ba
136. Samsam M, Ahangari R, Naser SA. Pathophysiology of autism spectrum disorders: revisiting gastrointestinal involvement and immune imbalance. World J Gastroenterol. 2014; 20(29): 9942-9951. doi: 10.3748/wjg.v20.i29.9942
137. White JF. Intestinal pathophysiology in autism. Exp Biol Med (Maywood). 2003; 228: 639-649.
138. Chaidez V, Hansen RL, Hertz-Picciotto I. Gastrointestinal problems in children with autism, developmental delays or typical development. J Autism Dev Disord. 2014; 44(5): 1117-1127. doi: 10.1007/s10803-013-1973-x
139. Mazefsky CA, Schreiber DR, Olino TM, Minshew NJ. The association between emotional and behavioral problems and gastrointestinal symptoms among children with high-functioning autism. Autism. 2014; 18(5): 493-501. doi: 10.1177/1362361313485164
140. Buie T, Campbell DB, Fuchs GJ 3rd, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics. 2010; 125(Suppl 1): S1-S18. doi: 10.1542/peds.2009-1878C
141. Mazurek MO, Vasa RA, Kalb LG, et al. Anxiety, sensory over-responsivity, and gastrointestinal problems in children with autism spectrum disorders. J Abnorm Child Psychol. 2013; 41(1): 165-176. doi: 10.1007/s10802-012-9668-x
142. Mikami N, Watanabe K, Hashimoto N, et al. Calcitonin gene-related peptide enhances experimental autoimmune encephalomyelitis by promoting Th17-cell functions. Int Immunol. 2012; 24(11): 681-691. doi: 10.1093/intimm/dxs075
143. Jusek G, Reim D, Tsujikawa K, Holzmann B. Deficiency of the CGRP receptor component RAMP1 attenuates immunosuppression during the early phase of septic peritonitis. Immunobiology. 2012; 217(8): 761-767. doi: 10.1016/j.imbio.2012.04.009
144. Park SH, Sim YB, Kim CH, Lee JK, Lee JH, Suh HW. Role of α-CGRP in the regulation of neurotoxic responses induced by kainic acid in mice. Peptides. 2013; 44: 158-162. doi: 10.1016/j.peptides.2013.04.001
145. Sardi C, Zambusi L, Finardi A, et al. Involvement of calcitonin gene-related peptide and receptor component protein in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014; 271(1-2): 18-29. doi: 10.1016/j.jneuroim.2014.03.008
146. Engel MA, Khalil M, Siklosi N, et al. Opposite effects of substance P and calcitonin gene-related peptide in oxazolone colitis. Dig Liver Dis. 2012; 44(1): 24-29. doi: 10.1016/j.dld.2011.08.030
147. Yang L, Sakurai T, Kamiyoshi A, et al. Endogenous CGRP protects against neointimal hyperplasia following wire-induced vascular injury. J Mol Cell Cardiol. 2013; 59: 55-66. doi: 10.1016/j.yjmcc.2013.02.002
148. Li J, Carnevale KA, Dipette DJ, Supowit SC. Renal protective effects of α-calcitonin gene-related peptide in deoxycorticosterone-salt hypertension. Am J Physiol Renal Physiol. 2013; 304(7): F1000-F1008. doi: 10.1152/ajprenal.00434.2012
149. Mai TH, Wu J, Diedrich A, Garland EM, Robertson D. Calcitonin gene-related peptide (CGRP) in autonomic cardiovascular regulation and vascular structure. J Am Soc Hypertens. 2014; 8(5): 286-296. doi: 10.1016/j.jash.2014.03.001
150. Smillie SJ, King R, Kodji X, et al. An ongoing role of α-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension. 2014; 63(5): 1056-1062. doi: 10.1161/HYPERTENSIONAHA.113.02517
151. Riera CE, Huising MO, Follett P, et al. TRPV1 pain receptors regulate longevity and metabolism by neuropeptide signaling. Cell. 2014; 157(5): 1023-1036. doi: 10.1016/j.cell.2014.03.051
152. Steculorum SM, Brüning JC. Die another day: a painless path to longevity. Cell. 2014; 157(5): 1004-1006. doi: 10.1016/j.cell.2014.05.013
153. Bray N. Neuroendocrinology: a long pain-free life. Nat Rev Drug Discov. 2014; 13(7): 495. doi: 10.1038/nrn3778